The Wisconsin State Journal reports that the University of Wisconsin Madison (UW-Madison) Carbone Cancer Center will lead a Phase I clinical trial focusing on an experimental cancer drug developed by Cellectar Biosciences. Patients (children and adolescents) will be treated at UW’s American Family Children’s Hospital.
CLR131, the investigational drug, includes high doses of radioactive iodine to kill cancer cells. About 11,000 children and adolescents are diagnosed with solid tumors (including brain and lymphomas) annually.
Madison, WI based Cellectar Biosciences is a radiopharmaceutical company focusing on the development of compounds to detect, treat and monitor various cancers. It was formed in 2003.
Cellectar Biosciences was formerly known as Cellectar, LLC and changed its name in 2008. The company was founded in 2003 and is based in Madison, Wisconsin.
Mario Otto, MD, Ph.DSource: madison.com